Immunome, Inc.

NASDAQ:IMNM

Biotechnology

Healthcare
$16.61 -2.26%

-$0.42 today

Market cap
$1.96B
Beta
2.07
P/E (TTM)
-9.1
EPS (TTM)
-$1.99
52W Low $7.96High $27.65

Volume 0.88M

Average 1.23M

Income Statement

Follow revenue through to earnings.

Revenue

$6.94M

FY 2025 · Annual

-23.2% YoY

Operating Income

-$214.11M

FY 2025 · Annual

Net Income

-$212.39M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0014.02M9.04M6.94M
Cost of Revenue00002.96M
Gross Profit0014.02M9.04M3.99M
Gross Margin——100.0%100.0%57.4%
Research & Development14.11M23.27M23.09M129.54M174.33M
Selling, General & Admin11.09M13.63M19.66M32.96M43.77M
Operating Expenses25.2M36.9M123.55M314.84M218.1M
Depreciation & Amortization755K631K728K2.1M2.96M
EBITDA(23.95M)(36.26M)(28M)(151.35M)(209.44M)
EBITDA Margin——-199.7%-1674.1%-3017.4%
Operating Income(25.2M)(36.9M)(109.53M)(305.8M)(214.11M)
Operating Margin——-781.4%-3382.4%-3084.8%
Interest Income10K5K2.72M12.84M11.72M
Interest Expense10K5K000
Other Income / Expenses493K5K2.72M12.84M1.72M
Income Before Tax(24.71M)(36.9M)(106.81M)(292.96M)(212.39M)
Pre-Tax Margin——-761.9%-3240.4%-3060.0%
Income Tax Expense00000
Net Income(24.71M)(36.9M)(106.81M)(292.96M)(212.39M)
Net Margin——-761.9%-3240.4%-3060.0%
EPS (Basic)(2.14)(3.09)(5.38)(5.00)(2.43)
EPS (Diluted)(2.14)(3.09)(5.38)(5.00)(2.43)
Weighted Avg Shares11.54M12.13M19.84M58.64M87.35M
Weighted Avg Shares (Diluted)11.54M12.13M19.84M58.64M87.35M

IMNM Earnings Waterfall · TTM

NASDAQ:IMNM · Revenue to Net Income

Key Ratios

EPS$-2.65
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-8.4
P/S Ratio0.0

Analysis

$0 of revenue converted into -$282.6M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-2.65, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
S-3ASRS-3ASR filingNov 9, 2026
10-QQuarterly reportNov 9, 2026
8-KCurrent reportNov 9, 2026
S-3ASRS-3ASR filingNov 9, 2026
SC 13GSC 13G filingOct 30, 2026

How much revenue does IMNM generate?

Immunome, Inc. (IMNM) reported $6.94M of revenue in fiscal 2025.

Is IMNM profitable?

Immunome, Inc. (IMNM) reported -$212.39M of net income, with a net margin of -3060.0%.